Reaction

Focal Segmental Glomerulosclerosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,578 reports · 47 co-occurring drugs

As of the last recalculation, Focal Segmental Glomerulosclerosis appears in 1,578 FAERS reports alongside 47 co-occurring drug terms. The strongest observed disproportionality signal is BASILIXIMAB (PRR 149.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Basiliximab	123	149.5	151.1
Valganciclovir Hydrochloride Powder,	63	70.9	71.3
Tacrolimus Ointment 0.1%	423	60.8	61.1
Tacrolimus Extended-Release Capsules	423	60.7	60.9
Tacrolimus	494	60.1	60.3
Valganciclovir	70	51.2	51.4
Valganciclovir Hydrochloride	70	51.2	51.4
Mycophenilic Acid	75	50.1	50.2
Anti-Thymocyte Globulin (Rabbit)	28	46.6	46.8
Mycophenolic Acid	102	44.9	45.0
Mycophenolate Mofetil	352	43.7	43.8
Mycophenolate Mofetil Hydrochloride	352	43.6	43.7
Ganciclovir	25	32.7	32.8
Ganciclovir Sodium	25	31.6	31.7
Testosterone	47	27.3	27.4
Sirolimus	26	25.9	25.9
Labetalol	23	23.1	23.1
Cyclosporine	154	20.1	20.1
Methylprednisolone	162	17.1	17.1
Mometasone	21	15.3	15.3
Abacavir Sulfate	11	15.0	15.0
Everolimus Tablets	17	13.5	13.5
Sodium Bicarbonate	23	13.2	13.2
Sodium Bicarbonate Injection,	23	13.2	13.2
Nystatin Ointment	24	12.2	12.3
Nystatin Cream	24	12.2	12.2
Nystatin	24	11.7	11.7
Prednisolone	145	11.6	11.6
Prednisolone Oral	145	11.6	11.6
Prednisolone Oral Solution	145	11.6	11.6
Sevelamer Carbonate	10	11.5	11.6
Busulfan	12	10.1	10.1
Trazodone Hydrochloride	11	9.3	9.3
Tenofovir Disoproxil Fumarate Tablets	6	9.2	9.2
Rituximab	133	9.0	9.0
Pyrazinamide	6	8.5	8.5
Ribavirin	40	8.4	8.4
Isoniazid	10	8.2	8.2
Lenvatinib	19	7.7	7.7
Imatinib	10	7.5	7.5
Lamivudine Oral	14	7.4	7.4
Sorafenib	11	7.0	7.0
Somatropin	33	6.0	6.0
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	4	5.3	5.3
Tenofovir Disoproxil Fumarate	12	4.8	4.8
Buprenorphine	21	3.0	3.0
Aflibercept	7	3.0	3.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.